Nunzia Pharmaceutical (NUNZ) Ratios
Nunzia Pharmaceutical Ratios
NUNZ's free cash flow for Q3 2022 was $-113.09K. For the 2022 fiscal year, NUNZ's free cash flow was increased by $0.00 and operating cash flow was $-113.09K. See a summary of the company’s cash flow.
| Ratios | Dec 21 | Dec 20 | Dec 19 | Dec 18 | Dec 17 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quick Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Solvency Ratio | -783.73 | -2774.87 | 6.12 | -0.03 | 0.14 |
| Operating Cash Flow Ratio | -0.87 | -247.23 | -0.17 | 0.00 | 0.00 |
| Short-Term Operating Cash Flow Coverage | -0.89 | -854.21 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -99.17K | $ -36.40K | $ -22.57K | $ -293.97K | $ -275.39K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 18.99 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -1.03 | -0.39 | 0.00 | -0.08 | -0.08 |
| Debt-to-Capital Ratio | 29.81 | -0.63 | 0.00 | -0.08 | -0.09 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.63 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt Service Coverage Ratio | -783.69 | -0.10 | 0.00 | -1.18 | -0.57 |
| Interest Coverage Ratio | -41923.15 | -0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.32 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.00 | -0.00 | 0.00 | -0.85 | -1.76 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.00% | 256862.53% | 100.00% | 68.36% | 100.00% |
| Return on Assets (ROA) | -1521431.14% | 0.00% | 0.00% | 0.00% | 0.00% |
| Return on Equity (ROE) | 82894.04% | 170049.71% | 148.99% | 6.32% | 4.74% |
| Return on Capital Employed (ROCE) | 82890.08% | 108.03% | 148.99% | 9.24% | 4.74% |
| Return on Invested Capital (ROIC) | -2387913.98% | 152.03% | 148.99% | 10.03% | 5.17% |
| Return on Tangible Assets | -1521431.14% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings Yield | -39.32% | -11.82% | -0.00% | -0.00% | -0.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.03 | -0.00 | 0.00 | 0.00 |
| Free Cash Flow Per Share | -0.00 | -0.03 | -0.00 | 0.00 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.89 | -391.30 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -0.04% | -1.05% | -0.00% | 0.00% | 0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.54 | -8.46 | -81460.95 | -135449.89 | -196846.30 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -2108.06 | -14387.58 | -121370.51 | -8559.18 | -9322.99 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2287.78 | -94.96 | -721036.64 | 0.00 | 0.00 |
| Price-to-Operating Cash Flow Ratio | -2287.78 | -94.96 | -721036.64 | 0.00 | 0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | -0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value Multiple | -2.55 | -94.55 | 19822.31 | -92600.48 | -196848.06 |
| Enterprise Value | 198.62M | 854.70M | 2.74B | 2.52B | 2.57B |
| EV to EBITDA | -2.55 | -94.55 | 19822.31 | -92600.48 | -196848.06 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2288.90 | -94.97 | -721036.64 | 0.00 | 0.00 |
| EV to Operating Cash Flow | -2288.90 | -94.97 | -721036.64 | 0.00 | 0.00 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.26 | -0.35 | -0.00 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 11.18 | 1.00 | 0.85 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.00 | 1.00 | 0.11 | 0.00 | 0.00 |
Currency in USD